In a descriptive review of literature about the role of IFN-I in treating COVID-19, it is highlighted that IFN-α use at the early phase of COVID-19 presents a positive outcome, but IFN-β-1a and -1b are more effective to hinder COVID-19 (55). This evidence concerns the gene IFNA1 and COVID-19.